AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in pre-clinical development.
Roche Pharma India reported the launch of its blockbuster advancement drug, Ocrevus (ocrelizumab), for the treatment of multiple sclerosis (MS), growing its nervous system science portfolio to take special care of neglected needs of various...
Bitterroot Bio, an innovator in imaginative medicines for cardiovascular ailments, and Biotheus, a trailblazer in monoclonal and multi-explicit immunizer configuration, reported a long term research coordinated agreement. This alliance will...
Eli Lilly anticipates to introduce its obesity drug tirzepatide in India as soon as the following year, David Ricks, the U.S. drugmaker's President added. "We're open to any way to reach more patients as long as it makes sense for the company...
Japan's Takeda Drug is communicating with Indian controllers to make its dengue vaccine accessible in the country, the drugmaker's worldwide head of immunizations, Gary Dubin added. "We are in talks with regulators...
Bristol Myers Squibb has established a new facility in Hyderabad. The new global site will expand the company's drug development, IT, and digital capabilities and is expected to employ more than 1,500 people.
Apollo Health and Lifestyle Limited, one of India’s largest retail healthcare companies, has selected Oracle Fusion Cloud Enterprise Resource Planning (ERP) to optimize its financial operations and increase productivity.
The government has decided to take action against pharma units that are flouting norms by manufacturing nutraceuticals, health supplements and drugs in the same facility, said people with knowledge of the development.
According to a report by HDFC Securities, pharmaceutical companies, which have suffered in the last two years due to the pandemic and the country's instability, are showing new signs of recovery.
GSK plc announced positive headline results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhea in adolescents and adults.
, CDSCO.jpg)
.jpg)